Plus Therapeutics, Inc. announced that its subsidiary, CNSide Diagnostics, will present data at the SNO/ASCO CNS Metastases Conference from August 14-16, 2025, in Baltimore, MD. The presentations will ...
Nine patients participated in Stage 1 of the study, of which eight were evaluable for efficacy. Progression-free survival (PFS) in this initial group of patients was determined to be 8.4 months. The ...
HOUSTON, July 10, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform ...
AUSTIN, Texas, July 25, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (PSTV) (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results